Related references
Note: Only part of the references are listed.Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?
Olga Anczukow et al.
HUMAN MUTATION (2008)
CHEK2* 1100delC genotyping for clinical assessment of breast cancer risk:: Meta-analyses of 26,000 patient cases and 27,000 controls
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
E. M. Bahassi et al.
ONCOGENE (2008)
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice
Dipankar Ray et al.
CANCER RESEARCH (2007)
The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model
El Mustapha Bahassi et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2007)
Increased risk of breast cancer associated with CHEK2*1100delC
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The CHEK2 gene and inherited breast cancer susceptibility
H. Nevanlinna et al.
ONCOGENE (2006)
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer
Serena Bonin et al.
VIRCHOWS ARCHIV (2006)
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant
EL Kwak et al.
CANCER RESEARCH (2006)
German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer
MU Rashid et al.
EUROPEAN JOURNAL OF CANCER (2005)
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes
DJ Hunter et al.
NATURE REVIEWS CANCER (2005)
Cancer risks and mortality in heterozygous ATM mutation carriers
D Thompson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects
LP Stabile et al.
CANCER RESEARCH (2005)
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands
PA Hershberger et al.
CANCER RESEARCH (2005)
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
O Kilpivaara et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant
GH de Bock et al.
JOURNAL OF MEDICAL GENETICS (2004)
Association studies for finding cancer-susceptibility genetic variants
PDP Pharoah et al.
NATURE REVIEWS CANCER (2004)
Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women
DM Friedrichsen et al.
BREAST CANCER RESEARCH (2004)
CHEK2 variants associate with hereditary prostate cancer
EH Seppälä et al.
BRITISH JOURNAL OF CANCER (2003)
Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint
I Hassepass et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Mutations in CHEK2 associated with prostate cancer risk
XY Dong et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome
N Sodha et al.
HUMAN MUTATION (2002)
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints
H Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
H Takai et al.
EMBO JOURNAL (2002)
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner
A Hirao et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response
MT Jack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations
H Meijers-Heijboer et al.
NATURE GENETICS (2002)
Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway
SQ Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
AC Antoniou et al.
GENETIC EPIDEMIOLOGY (2001)
Breast cancer genetics: What we know and what we need
KN Nathanson et al.
NATURE MEDICINE (2001)
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
J Falck et al.
NATURE (2001)
Role of the Cdc25A phosphatase in human breast cancer
MG Cangi et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Induction of mammary gland development in estrogen receptor-α knockout mice
WP Bocchinfuso et al.
ENDOCRINOLOGY (2000)
Rapid destruction of human Cdc25A in response to DNA damage
N Mailand et al.
SCIENCE (2000)
Share Paper
